First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma.
Simple Summary: Treatment of patients with mantle cell lymphoma is rapidly evolving, driven by several recent clinical trials showing that combining covalent Bruton's tyrosine kinase inhibitors with other therapies can lead to improved outcomes. Although these newer treatment approaches expand avail...
| Published in: | Current Oncology Vol. 33; no. 7; pp. 426 - 446 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Published: |
MDPI
Jul2026
|
| Online Access: | View this record in EBSCOhost |